IMAGE

Fig. S3

ID
ZDB-IMAGE-180731-10
Source
Figures for Hsieh et al., 2018
Image
Figure Caption

Fig. S3

VCAP1X2 morphant embryos exhibited similar cardiac defects to VCAP1X2 mutant embryos. (A) A diagram of VCAP1X2 spMO target site at the boundary between intron 1 and exon 2 is shown. (B) Splicing of exon 1 and exon 2 was disrupted in VCAP1X2 morphant compared to wild-type (WT) embryos, indicated by the 702 bp RT-PCR product using forward and reverse primers indicated by red arrows in (A). (C) Expression of EGFP or VCAP1X2 in ventricles of hearts in Tg(myl7: EGFP; myl7: H2AFZ mcherry), 5mm spMO-injected, and VCAP1X2 spMO-injected embryos. Higher VCAP1X2 expression was detected in the heart ventricle in Tg (myl7: EGFP; myl7: H2AFZ mcherry) embryos and 5mm spMO-injected embryos. No VCAP1X2 expression was detected in the VCAP1X2 spMO-injected embryos at 96 hpf (n = 15 per condition, N = 3). v, ventricle. Scale bar, 30 μm. (D) Paraffin sections stained with hematoxylin and eosin showed thinner ventricular compact layer in VCAP1X2 spMO-injected morphants compared to un-injected wild-type (WT) or 5mm spMO-injected control embryos at 120 hpf. Such defects could be rescued by co-injection with full-length (FL) VCAP1X2 but not with LacZ mRNA (n = 10 per condition). Scale bar, 25 μm. v, ventricle, a, atrium. (E) VCAP1X2 spMO-injected Tg(myl7:EGFP; myl7:H2AFZ mCherry) embryos exhibited decreased ventricular fractional shortening in the heart compared to un-injected or 5mm spMO-injected transgenic embryos and co-injection of △N or full-length (FL) VCAP1X2 mRNA, but not SP, △N Y2F or Y2F VCAP1X2 mRNA, could rescue decreased ventricular fractional shortening in the heart of VCAP1X2 spMO-injected transgenic embryos at 72 hpf (n = 20 per condition, N = 3). Error bars indicate standard error. (F) VCAP1X2 spMO-injected Tg(myl7:EGFP; myl7:H2AFZ mCherry) embryos exhibited reduced ventricular cardiomyocyte (CM) number compared to uninjected or 5mm spMO-injected transgenic embryos at 72 hpf. The defect could be rescued by co-injection of △N or full-length (FL) VCAP1X2 mRNA, but not SP, △N Y2F or Y2F VCAP1X2 mRNA (n = 20 per condition, N = 3). Error bars indicate standard error. Quantitative data were analyzed by ANOVA with Bonferroni multiple comparisons. Treatments that are not statistically different (α = 0.05) from each other are labeled with the same letter.

Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Sci. Rep.